

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**EFFECT OF CAFFEINE INGESTION ON ASPECTS OF
ENDURANCE PERFORMANCE AND COGNITION IN
CYP1A2 HETEROZYGOUS A/C MALE RECREATIONAL
ATHLETES**

By

Kyle Southward

A Thesis presented in partial fulfilment for the requirements
of a Master of Science in Sport and Exercise Science at
Massey University, Albany, New Zealand

2016

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

ACKNOWLEDGEMENTS

I would like to thank all the participants who gave a large portion their time and effort to this challenging study. Without their participation this study would not have been possible and is greatly appreciated.

I would also like to thank my supervisors Dr Ajmol Ali and Dr Kay Rutherford-Markwick for their patience, guidance and motivation in producing this thesis. They provided me with the right tools and skills needed to complete my thesis.

Big thanks to Megan Wraith, Angela Tyrrell and Frances Martin for their assistance in data collection, continued motivation and stimulating discussions. I would like to also thank Kate McMaster for her technical assistance and use of the Sport Science Laboratory where the study was conducted.

Finally I would like to thank my family for their continued support without whom I would not be where I am today.

ABSTRACT

Background: Globally, caffeine is the most widely accessible psychoactive drug and has been shown to improve endurance performance as well as aspects of cognition, mood and perceptual responses during exercise. However, the ergogenic effects of caffeine between individuals are variable, and the cause of this variability is unknown. The CYP1A2 gene is known to mediate caffeine metabolism and has been suggested as a contributor to the variability of the ergogenic effects of caffeine.

Purpose: To investigate the effects of CYP1A2 genotype on exercise performance (10 km time trial), sleep, mood, cognition and perceptual responses following caffeine ingestion in adult male recreational athletes.

Methods: 16 recreationally trained athletes (age = 26.9 ± 7.93 y; weight = 77.00 ± 9.04 kg) volunteered for this study. Participants completed a familiarisation session at least one week before the first trial and a saliva sample was collected for testing of the participants' CYP1A2 genotype. Participants completed two trials one week apart in a randomised double-blind placebo-controlled cross-over design. Participants were asked to abstain from caffeine ingestion and keep a food diary for 24 h prior to the trial. Participants wore an actigraph, and completed a sleep diary and Leeds Sleep Evaluation Questionnaire (LSEQ) every day for the two week duration of the trials starting 3 days before the first trial and ending 3 days after the second trial. The main trial consisted of a set of pre- and post-ingestion measures which included leg power by vertical jump height (squat jump – SJ; countermovement jump – CMJ), leg strength by maximal voluntary concentric and eccentric contraction of the knee extensors (isokinetic dynamometer), perceptual (feeling scale – FS; felt arousal scale – FAS), mood (profile of mood states – POMS), cognition (digit vigilance – DV; Corsi blocks – CB; rapid visual information processing – RVIP) and heart rate. Pre- and post-ingestion urine, saliva and blood samples were also collected for analysis of caffeine metabolism and genotype. Following completion of pre-ingestion measures, participants consumed a capsule containing either anhydrous caffeine ($6 \text{ mg}\cdot\text{kg}^{-1}$) or placebo (maltodextrin) and were instructed to rest quietly for 50 min. Following post-ingestion measures, participants completed a 10-km time trial run. Perceptual

measures (FS and FAS) including ratings of perceived exertion (RPE) were recorded every 2.5 km and heart rate was recorded every 1 km. A venous blood sample and saliva sample was collected at 5 km and 10 km. At completion of the 10-km time trial all post-ingestion measures were repeated, followed by another 50 min rest period. After the second 50 min rest period the participants completed the perceptual, mood and cognitive measures and further blood, urine and saliva samples were collected. Participants returned 24 and 48 h post-ingestion to repeat all post-ingestion measures and another blood, urine and saliva sample was collected. This protocol was then repeated 1 week later for the alternate treatment (placebo or caffeine). The effect of treatment (caffeine, placebo) and the interaction effect of treatment x time were assessed using a repeated measures ANOVA. A student's t-test was used to measure differences between Leeds sleep evaluation questionnaire (LSEQ) and actigraph data.

Results: Fourteen of sixteen participants were heterozygous A/C CYP1A2 for the CYP1A2 genotype and therefore results based on genotypes could not be compared as originally intended. Plasma caffeine, paraxanthine and theophylline concentrations were all elevated following caffeine ingestion ($P < 0.05$) peaking at 10-km, 1 hour after the 10-km run and 24 hours post caffeine ingestion respectively. Caffeine did not significantly improve 10-km run times. Eccentric leg strength but not concentric leg strength was improved following caffeine ingestion ($P < 0.05$). Squat jump height but not countermovement jump height was improved following caffeine ingestion ($P < 0.05$). Digit vigilance reaction times were decreased significantly following caffeine ingestion ($P < 0.05$) and a trend of decreased rapid visual information processing (RVIP) reaction times were seen ($P < 0.1$), however, no improvements in the accuracy during cognitive tests were seen following caffeine ingestion. A trend of increased heart rate ($P < 0.1$) during exercise was observed following caffeine ingestion, but no significant differences in heart rate before and after exercise were observed.

Conclusions: While no overall, significant improvements in run time occurred following caffeine ingestion, 11 of 14 participants had a faster run time following caffeine ingestion compared to placebo. Caffeine, rather than the metabolites of caffeine, is likely the main cause of any observed ergogenic effects following caffeine ingestion as the improvements in reaction times, mood and

endurance performance occurred when plasma caffeine concentration was elevated but plasma caffeine metabolite concentrations were low. It was found that caffeine ingestion improves endurance performance and reaction times during cognitive tasks. Taken together, the pharmacokinetics of the caffeine and caffeine metabolite peaks suggest that for athletes with the A/C CYP1A2 genotype ingestion of caffeine 1.5 – 2 h prior to an event may be more beneficial for endurance performance compared to the usual recommendations of taking caffeine 1 h prior to exercise.

Keywords: caffeine, endurance exercise, CYP1A2, performance, genetics

TABLE OF CONTENTS

	Page
Acknowledgements	i
Abstract	ii
Table of Contents	v
List of Figures	ix
List of Tables	xii
1.0 INTRODUCTION	1
1.1 Hypotheses	6
2.0 LITERATURE REVIEW	7
2.1 Caffeine use as an ergogenic aid	7
2.2 Mechanisms of action	8
2.2.1 Fat oxidation	8
2.2.2 Blood glucose and lactate	10
2.2.3 Catecholamines	12
2.2.4 Ionic balance	14
2.2.5 Adenosine receptor antagonism	16
2.2.6 Pain perception	18
2.2.7 Rating of perceived exertion (RPE)	20
2.2.8 β -endorphins	21
2.2.9 Caffeine metabolites	21
2.3 Effects of caffeine on mood, perceptual responses and cognition	23
2.3.1 Mood	23
2.3.2 Perceptual responses	25
2.3.3 Cognition	28

2.4	Effects of caffeine ingestion on strength and power	29
2.5	Effects of caffeine ingestion on endurance performance	32
2.6	Effects of caffeine ingestion on sleep quality	34
2.7	Effects of genetics on caffeine pharmacokinetics	35
2.8	Effect of genetics on the ergogenic effect of caffeine during endurance exercise	37
2.9	Summary	38
3.0	METHODOLOGY	39
3.1	Participants	39
3.2	Participant control	39
3.3	Description of physiological tests and measures	40
3.3.1	Height and weight measures	40
3.3.2	Heart rate	40
3.3.3	Urine collection and storage	40
3.3.4	Saliva collection and storage	40
3.3.5	Blood sampling and storage	41
3.3.6	Urine and plasma caffeine concentration analysis	42
3.3.7	Vertical jump height	42
3.3.8	Leg strength and power	43
3.3.9	10-km time trial run	43
3.4	Description of perceptual scales	44
3.5	Description of cognitive tests	44
3.6	Description of sleep quality measures	45
3.7	Familiarisation protocol	46
3.8	Study design	46
3.9	Data and statistical analysis	49

4.0	RESULTS	50
4.1	Participants	50
4.2	10-km time trial run	50
4.3	Heart rate	52
4.4	Leg strength and power	53
4.5	Perceptual responses	57
4.6	Mood	61
4.7	Cognition	62
4.8	Sleep data	66
4.9	Blood metabolites	68
5.0	DISCUSSION	73
5.1	Kinetics of caffeine and caffeine metabolites	73
5.2	10-km time trial run	75
5.3	Leg strength	76
5.4	Leg power	77
5.5	Perceptual responses	78
5.6	Mood	80
5.7	Cognition	81
5.8	Sleep data	82
5.9	Conclusions	83
5.10	Limitations	84
5.11	Future directions	85
6.0	REFERENCES	86
7.0	APPENDICES	108
	Appendix 1 – Ethical Approval	109

Appendix 2 – Participant information sheet	110
Appendix 3 – Participant consent form	114
Appendix 4 – Health screening questionnaire	115
Appendix 5 – Participants screening questionnaire	118
Appendix 6 – Food Diary	120
Appendix 7 – Saliva collection method and standard operating procedure	125
Appendix 8 – DNA extraction method from saliva	126
Appendix 9 – Plasma and urine caffeine and caffeine metabolite HPLC assay	127
Appendix 10 – Rating of perceived exertion scale (RPE)	128
Appendix 11 – Feeling scale (FS)	129
Appendix 12 – Felt arousal scale (FAS)	130
Appendix 13 – Profile of mood states short form (POMS - 40)	131
Appendix 14 – Sleep diary and Leeds Sleep Evaluation Questionnaire (LSEQ)	133

LIST OF FIGURES

Figure 2.1 – A visual depiction of the affect circumplex model used for plotting the perceptual response to exercise.	27
Figure 3.1 – Saliva collection method.	41
Figure 3.2 – Detailed schematic diagram of main trials showing time of sample collection, physiological measures and cognitive tests.	48
Figure 4.1 – Run times in CAFF and PLA split between the initial 5 km and last 5 km.	51
Figure 4.2 – 10 km run times in both the placebo trial (y-axis) and the caffeine trial (x-axis).	51
Figure 4.3 – Heart rate during the 10 km time trial in CAFF and PLA trials.	52
Figure 4.4 – Maximal concentric knee extensor torque by participants in the CAFF and PLA trials.	53
Figure 4.5 – Maximal eccentric knee extensor torque by participants in the CAFF and PLA trials.	54
Figure 4.6 - Squat jump (SJ) height during CAFF and PLA trials.	55

Figure 4.7 – Countermovement jump (CMJ) height during CAFF and PLA trials.	56
Figure 4.8 – Feeling scale (FS) scores of pleasure and displeasure during CAFF and PLA trials.	58
Figure 4.9 – Felt arousal scale scores of activation during CAFF and PLA trials.	59
Figure 4.10 – Feeling scale (FS) and felt arousal scale (FAS) ratings plotted in a circumplex model.	60
Figure 4.11 – Profile of mood states fatigue subset results during CAFF and PLA trials.	61
Figure 4.12 – Profile of mood states (POMS) vigour subset scores during CAFF and PLA trials.	62
Figure 4.13 – Digit vigilance test reaction times during CAFF and PLA trials.	63
Figure 4.14 – Rapid visual information processing (RVIP) test reaction times during CAFF and PLA trials.	64
Figure 4.15 – Plasma caffeine concentration during CAFF and PLA ingestion trials.	68

Figure 4.16 – Plasma paraxanthine concentration during CAFF and PLA ingestion trials.	69
Figure 4.17 – Plasma theobromine concentration during CAFF and PLA trials.	70
Figure 4.18 – Plasma theophylline concentration during CAFF and PLA trials.	71
Figure 4.19 – Individual plasma A) caffeine, B) paraxanthine and C) theophylline concentration over the duration of the caffeine trial.	72

LIST OF TABLES

Table 2.1 – Summary of literature on to the effects of caffeine ingestion on pain during exercise.	19
Table 2.2 - Summary of literature on the effects of caffeine ingestion on power exercise.	31
Table 2.3 – Summary of literature on the effects of caffeine ingestion on strength exercise.	32
Table 4.1 – Mean \pm standard deviation of ratings of perceived exertion (RPE) during the 10 km time trial for CAFF and PLA trials.	57
Table 4.2 – Mean \pm standard deviation of digit vigilance and rapid visual information processing (RVIP) accuracy in CAFF and PLA trials.	63
Table 4.3 – Mean \pm standard deviation of Corsi span scores in CAFF and PLA trials.	65

Table 4.4 – Mean \pm standard deviation LSEQ questions; ease of getting to sleep (EGTS), perceived quality of sleep (PQS), ease of awakening from sleep (EAFS), behaviour following awakening (BFA) 66

Table 4.5 – Mean \pm standard deviation of actigraphy data after caffeine and placebo ingestion. 67